As a corollary, we demonstrated that relieving these repressive circuitries with clinically approved or experimental HDAC inhibitors is essential to convert PPARγ into a tractable therapeutic target and that combination therapy elicits synergistic antitumor effects against preclinical models of TNBC and endocrine-refractory breast cancer. Here, PPARG is linked to breast carcinoma.